Open access peer-reviewed chapter
Abstract
Epilepsy is a neurological disorder characterised by recurrent seizures, which can significantly impact patient’s quality of life. While current management strategies for epilepsy, such as antiepileptic drugs and surgery, are effective for many patients, there is a need for novel therapies that can provide better seizure control and improve patients’ outcomes. Oxytocin, a neuropeptide known for its role in social bonding and trust, has emerged as a promising therapy for epilepsy. Preclinical studies have shown that oxytocin can reduce seizure activity and improve seizure outcomes in animal models of epilepsy. In contrast, clinical studies have suggested that oxytocin may reduce seizure frequency and severity in some epilepsy patients. This chapter reviews the current knowledge of oxytocin and epilepsy, including the potential mechanisms of oxytocin’s antiepileptic effects, the limitations and challenges of clinical studies, and future research directions and implications. The chapter also discusses the broader impact of oxytocin research on understanding social behaviour and neurological disorders. Overall, the chapter highlights the potential of oxytocin as a novel therapy for epilepsy management and underscores the need for further research.
Keywords
- oxytocin
- seizure control
- epilepsy management
- improved patient outcomes
- epilepsy
1. Introduction
Oxytocin, often called the “love hormone,” has garnered considerable attention for its profound effects on social behaviours and emotional bonding [1, 2, 3, 4, 5]. It fosters trust, empathy, and social connection [3, 4, 6]. However, recent research has uncovered additional dimensions of oxytocin’s influence, particularly in neurological disorders [7, 8, 9]. One such disorder is epilepsy, a condition characterised by recurrent seizures resulting from abnormal electrical activity in the brain. Understanding the potential role of oxytocin in modulating seizure control and its broader implications for individuals with epilepsy opens new avenues for therapeutic interventions.
Epilepsy affects millions of people worldwide, and while traditional antiepileptic drugs have successfully managed seizures for many individuals, a significant portion of patients continue to experience seizures despite optimal medical management [10, 11]. This treatment-resistant epilepsy poses challenges and underscores the need to explore alternative therapeutic approaches. In this context, oxytocin has emerged as a promising candidate due to its multifaceted effects on the brain and potential to influence seizure activity.
Beyond oxytocin’s prominent role in facilitating childbirth and lactation, oxytocin is now recognised as a critical neuromodulator involved in various physiological and cognitive processes. Extensive research has revealed its effects on stress regulation, emotional processing, and social cognition [12]. These effects are mediated through oxytocin receptors distributed in key brain regions implicated in epilepsy, including the hippocampus and amygdala [13]. Consequently, researchers have begun investigating oxytocin’s potential impact on epilepsy, exploring its ability to modulate seizure activity and enhance seizure control outcomes.
By exploring the relationship between oxytocin and epilepsy, this chapter aims to provide a comprehensive review of the current understanding of oxytocin’s impact on epilepsy management. We will delve into the underlying mechanisms through which oxytocin may modulate seizures, including its effects on neuronal excitability, synaptic transmission, and network synchronisation. Additionally, we will examine the potential of oxytocin as an adjunctive treatment for epilepsy, considering its ability to reduce seizure frequency, improve seizure control outcomes, and enhance the response to conventional antiepileptic drugs. Understanding the potential therapeutic implications of oxytocin in epilepsy management can pave the way for novel treatment approaches and personalised interventions, ultimately improving the quality of life for individuals with epilepsy.
2. Background
Oxytocin, a peptide hormone synthesised in the hypothalamus and released by the pituitary gland, has long been recognised for its crucial role in childbirth and lactation, facilitating maternal-infant bonding and promoting nurturing behaviours [14, 15, 16]. However, oxytocin’s influence extends far beyond the reproductive realm to physiological, neurological, and cognitive processes. In recent years, researchers have discovered that oxytocin acts as a versatile neuromodulator, exerting effects on various physiological and cognitive processes [17, 18, 19, 20].
Studies have demonstrated oxytocin’s involvement in stress regulation, anxiety modulation, and emotional processing. Oxytocin enhances social bonding among human beings by promoting trust, empathy, and prosocial behaviours [21, 22, 23, 24, 25]. It influences social cognition, including the perception of facial expressions, emotions, and social cues [26, 27, 28, 29, 30, 31, 32, 33, 34]. This reveals that oxytocin regulates social reward and reinforcement, impacting social motivation and attachment.
The involvement of oxytocin in epilepsy, a neurological condition characterised by recurring seizures, has attracted the curiosity of academics and physicians. Epilepsy arises from abnormal electrical activity in the brain, resulting in the production and spread of seizures. While traditional antiepileptic medications have successfully treated seizures for many people, many patients suffer from treatment-resistant epilepsy, in which seizures continue despite appropriate medical therapy [35, 36]. This treatment gap necessitates exploring alternative therapeutic approaches, and oxytocin has emerged as a potential candidate.
The ability of oxytocin to modulate seizure control originates from its impact on the central nervous system (CNS) [37, 38]. Oxytocin receptors, including the hippocampus and amygdala, are present throughout the brain and have been linked to both pro- and anticonvulsive characteristics, which appear to be dose- or time-dependent [39, 40]. Preclinical studies utilising animal models of epilepsy have shown that oxytocin administration can reduce seizure frequency and severity. Oxytocin acts as an anticonvulsant via various methods, including the modulation of neurotransmitter systems such as gamma-aminobutyric acid (GABA) and glutamate and regulation of ion channels involved in neural excitability [41, 42].
Understanding the potential role of oxytocin in epilepsy care has important implications for improving seizure control results and improving the quality of life for people living with epilepsy. Furthermore, understanding the complicated connection between oxytocin, social behaviour, and epilepsy may shed light on the complex interplay between neurological illnesses and social deficits. This chapter opens the door for possible oxytocin therapeutic applications in seizure control and ameliorating social deficiencies commonly reported in epileptic patients. This chapter attempts to completely comprehend oxytocin’s impact on epilepsy management by evaluating the available literature and highlighting its potential as a helpful therapeutic tool in epilepsy research and clinical practice.
2.1 Purpose of the chapter
The primary objective of this chapter is to provide a comprehensive understanding of the impact of oxytocin on epilepsy management. Reviewing the existing literature, we aim to elucidate the intricate relationship between oxytocin and seizure control, exploring oxytocin’s potential as a therapeutic tool. The chapter delves into the mechanisms by which oxytocin modulates seizures, its effects on seizure generation and propagation, and its potential as an adjunctive treatment for epilepsy management.
3. Oxytocin: the love hormone
This section described oxytocin and its physiological functions, particularly its role in social bonding and trust, as well as the mechanisms of oxytocin release and its effects on brain activity.
3.1 Oxytocin and its physiological functions, particularly its role in social bonding and trust
Oxytocin acts as a neurotransmitter and neuromodulator, influencing various brain regions involved in social behaviours and emotional processing. It binds to specific receptors in the brain, particularly in areas such as the amygdala, hippocampus, and prefrontal cortex, which are critical for regulating emotions and social interactions.
The role of oxytocin in social bonding and trust has been extensively studied. Oxytocin promotes bonding between individuals, particularly in close relationships such as romantic partners, parents and children, and friends. It enhances attachment and fosters intimacy and connection [43, 44]. Studies have shown that oxytocin increases feelings of trust and cooperation in social interactions, leading to more positive social behaviours [21, 22, 23, 24, 25, 45, 46]. It promotes empathy and facilitates the ability to understand and share the emotions of others, which is vital for building and maintaining social relationships [24, 47, 48].
Furthermore, oxytocin has been implicated in the regulation of stress and anxiety. It acts as a natural stress buffer, helping reduce stress responses and promote calmness and relaxation in social situations [44, 49, 50, 51]. Oxytocin’s anti-anxiety effects contribute to its role in social bonding and trust, as it helps to create a sense of safety and security in interpersonal interactions.
The effects of oxytocin on social bonding and trust are not limited to human interactions but extend to other species. Oxytocin has been shown to play a crucial role in maternal bonding in mammals, promoting the maternal-infant bond and facilitating nurturing behaviours [52, 53, 54]. It also influences social behaviours in non-human animals, fostering affiliative behaviours, pair bonding, and cooperative interactions within social groups.
Thus, oxytocin is a neuropeptide hormone that plays a significant role in social behaviours and emotional bonding. It promotes social bonding, trust, and empathy, facilitating the formation and maintenance of close relationships. Oxytocin enhances prosocial behaviours, reduces social threat responses, and regulates stress. Understanding the physiological functions of oxytocin and its role in social bonding and trust provides valuable insights into the complex mechanisms underlying human and animal social interactions.
3.2 The mechanisms of oxytocin release and its effects on brain activity
A complex interplay of physiological and psychological factors regulates the release of oxytocin. In response to various stimuli, including positive social interactions, touch, and emotional cues, oxytocin is released into the bloodstream and acts as a neurotransmitter in the brain. Oxytocin release can be triggered by childbirth, breastfeeding, and intimate physical contact, reinforcing individual bonding [55, 56, 57, 58].
Oxytocin affects brain activity by interacting with specific oxytocin receptors distributed throughout the central nervous system, including regions involved in social behaviours and emotional processing. Multiple pathways mediate the effects of oxytocin on brain activity. Oxytocin receptors are densely expressed in brain regions such as the amygdala, hippocampus, and prefrontal cortex, which are involved in emotional regulation, social cognition, and memory formation [59, 60, 61, 62].
Upon binding to oxytocin receptors, oxytocin triggers a cascade of intracellular signalling pathways that modulate neuronal excitability, synaptic transmission, and network connectivity [63, 64, 65, 66]. Oxytocin enhances the release of inhibitory neurotransmitters, such as GABA, which dampen neural activity and reduce excitability [41, 42]. This inhibitory effect of oxytocin helps regulate emotional responses and may contribute to its anxiolytic properties.
Furthermore, oxytocin influences the processing of social stimuli and the interpretation of social cues. It enhances social information’s salience and reward value, making social stimuli more rewarding and reinforcing social bonding [21, 22, 23, 24, 25, 67, 68, 69, 70, 71, 72]. Oxytocin also modulates the activity of brain regions involved in empathy and social cognition, promoting the understanding of others’ emotions and intentions [73, 74, 75, 76, 77].
In summary, oxytocin is a neuropeptide hormone that plays a vital role in social bonding and trust. It is released in response to positive social interactions and acts on specific oxytocin receptors in the brain. Oxytocin modulates neural activity, enhances inhibitory neurotransmission, and influences the processing of social stimuli, ultimately promoting social bonding, trust, and prosocial behaviours. Understanding the mechanisms of oxytocin release and its effects on brain activity provides valuable insights into the neurobiology of social behaviour and its potential therapeutic applications in various domains, including epilepsy management and social deficits in neurological disorders.
4. Epilepsy: overview and current management strategies
Epilepsy, a chronic neurological disorder characterised by unprovoked seizures, affects approximately 1% of the global population [78]. Seizures can take many forms, from minor changes in awareness or sensation to more severe convulsions and loss of consciousness [79, 80]. Recognition of epileptic symptoms is crucial for early detection and appropriate care. The symptoms can vary depending on the brain region abnormal electrical activity affects [81, 82, 83]. Some individuals may experience brief episodes of altered consciousness, such as staring or repetitive movements, while others may have more severe seizures involving convulsions and loss of muscle control [84, 85, 86, 87, 88].
Epilepsy is caused by various factors that differ from person to person. Epilepsy is frequently associated with structural abnormalities in the brain, such as deformities, injuries, tumours, strokes, or infections [84, 85, 86, 87, 88]. In some cases, genetic or hereditary factors contribute to the development of epilepsy, with specific gene mutations or inherited disorders increasing seizure susceptibility [79, 89, 90, 91]. Metabolic abnormalities, including electrolyte imbalances or glucose metabolism disorders, can also play a role in epilepsy [92, 93, 94]. Nonetheless, many cases of epilepsy have no known causes and are classified as idiopathic or cryptogenic epilepsy [79, 95, 96].
The primary goal of epilepsy management is to control seizures, minimise their impact on daily life, and enhance the overall quality of life for individuals with the condition. Antiepileptic drugs (AEDs) are the cornerstone of current management strategies, aiming to regulate brain electrical activity and reduce the frequency and severity of seizures [97, 98, 99, 100]. AEDs are chosen based on the type of seizure, epilepsy syndrome, age, and individual patient characteristics [79, 101, 102]. Lifestyle modifications, including regular sleep patterns, stress management, adherence to medication regimens, and routine medical monitoring, may complement medication-based management [103, 104, 105, 106, 107].
Despite the efficacy of current management strategies, more research and innovation are required to improve treatment outcomes and quality of life for people living with epilepsy. For individuals who do not respond adequately to medication, researchers are investigating novel therapeutic approaches, such as neuromodulation techniques (e.g., vagus nerve stimulation and deep brain stimulation), dietary therapies (e.g., ketogenic diet), and surgical interventions [79]. Neuromodulation techniques, such as vagus nerve stimulation, have shown promising results in reducing seizure frequency and improving seizure control [79, 108, 109, 110, 111, 112]. Some patients, particularly those with refractory epilepsy, have shown efficacy in dietary therapies such as the ketogenic diet [113, 114, 115, 116, 117]. Individuals with focal epilepsy who do not respond to medication may be candidates for surgical interventions such as resective surgery or responsive neurostimulation [118, 119, 120, 121, 122, 123].
Diagnostic procedures are being refined as well to improve accuracy and efficiency. Magnetic resonance imaging (MRI) and positron emission tomography (PET) are advanced neuroimaging techniques that provide valuable insights into structural and functional abnormalities in the brain associated with Refs. [124, 125, 126, 127]. Genetic profiling is increasingly utilised to identify specific gene mutations or genetic variants contributing to epilepsy susceptibility, allowing for more personalised treatment approaches [128, 129, 130, 131, 132].
Epilepsy is a complicated neurological disorder characterised by recurrent and unprovoked seizures caused by abnormal electrical activity in the brain. Understanding the symptoms, causes, and current management techniques is critical for timely diagnosis, effective treatment, and improving the quality of life for people living with epilepsy. Antiepileptic drugs are the foundation of therapy. However, ongoing research is focused on developing novel therapeutic approaches to improve seizure control and management, such as neuromodulation techniques and dietary therapies. Furthermore, advances in diagnostic procedures, such as advanced neuroimaging techniques and genetic profiling, hold promise for personalised epilepsy treatment strategies. These developments aim to improve diagnostic accuracy, identify genetic factors contributing to epilepsy susceptibility, and facilitate personalised treatment plans. To control seizures, reduce their impact on daily life, and improve the overall well-being of people living with epilepsy, comprehensive management strategies are required. Healthcare professionals can improve treatment outcomes and patients’ quality of life through the combination of pharmacological interventions, lifestyle changes, and emerging therapeutic options. Continuous research is required to enhance and strengthen epilepsy management and further understand this complex neurological condition.
Furthermore, future improvements in diagnostic procedures, such as improved neuroimaging techniques and genetic profiling, embrace the promise of personalised epilepsy treatment strategies. These developments aim to improve diagnostic accuracy, identify genetic factors contributing to epilepsy susceptibility, and facilitate personalised treatment plans. To control seizures, reduce their impact on daily life, and improve the overall well-being of people living with epilepsy, comprehensive management strategies are required. Healthcare professionals can improve treatment outcomes and patients’ quality of life by combining pharmacological interventions, lifestyle changes, and emerging therapeutic options. Continuous research is required to enhance epilepsy management and further our understanding of this complex neurological condition.
4.1 Epilepsy symptoms and causes
Epilepsy is a neurological condition characterised by two or more spontaneous seizures [133, 134]. Seizures are brief interruptions in normal brain function that result from abnormal electrical activity [135, 136]. Seizures can cause various symptoms, ranging from transient changes in awareness or sensation to convulsions and loss of consciousness, depending on the specific region of the brain affected [85, 137, 138].
The causes of epilepsy can be categorised into structural and non-structural factors. Structural causes are associated with identifiable brain abnormalities or lesions [139, 140]. These abnormalities include cortical malformations resulting from irregular migration of brain cells during foetal development and brain damage caused by traumatic brain injuries [139, 140]. Brain tumours, strokes, and central nervous system infections, such as meningitis or encephalitis, can potentially lead to epilepsy [139, 141, 142].
Alternatively, non-structural causes of epilepsy do not involve apparent structural abnormalities within the brain but are often linked to underlying functional or genetic factors [79, 143, 144, 145]. Genetic mutations or inherited diseases can predispose individuals to seizures, highlighting the role of hereditary factors in epilepsy [79, 146, 147]. Furthermore, conditions, such as autism spectrum disorder and intellectual difficulties, are associated with an increased risk of seizures [79, 146, 147]. Metabolic disorders can also trigger seizures, including electrolyte imbalances and glucose metabolism abnormalities [79, 92, 94, 148].
Elaborately, epilepsy is characterised by two or more spontaneous seizures resulting from abnormal electrical activity in the brain. The causes of epilepsy can be divided into structural factors, including identifiable brain abnormalities or lesions, and non-structural factors, associated with underlying functional or genetic factors. Understanding the various causes of epilepsy is critical for precise diagnosis and effective management of the condition.
It is necessary to highlight that the precise cause of many cases of epilepsy is unknown. Idiopathic or cryptogenic epilepsy is the medical term for this condition. Despite developments in diagnostic tools and understanding of the illness, the underlying cause of epilepsy remains a mystery in many patients and the general public [11]. Ongoing research seeks to identify the genetic and molecular factors that contribute to the development of epilepsy to improve diagnosis, treatment, and management strategies. Ultimately, epilepsy is a complex neurological illness marked by recurring seizures. Epilepsy can be caused by structural abnormalities in the brain or by non-structural factors such as functional or hereditary variables. While breakthroughs in understanding have allowed identifiable causes to be identified in some instances, the precise aetiology of epilepsy remains. Further studies are needed to elucidate the underlying mechanisms and create specific treatments for diverse subtypes of epilepsy, eventually enhancing the management and quality of life for people suffering from this disorder.
4.2 Current management strategies for epilepsy
The treatment of epilepsy is multidimensional, anticipating achieving optimal seizure control, minimising treatment adverse effects, and enhancing the overall quality of life for those living with epilepsy. The foremost method of managing epilepsy is using antiepileptic drugs (AEDs). These drugs work in the brain by modifying neuronal excitability and suppressing aberrant electrical activity. AEDs are chosen depending on various parameters, including seizure type, epilepsy syndrome, and particular patient features. The goal is to determine the best effective AED for each patient, delivering appropriate seizure control while minimising side effects [149, 150, 151]. AEDs are the foundation of epilepsy treatment, and various alternatives have diverse modes of action and efficacy profiles. Seizure type, epileptic syndrome, comorbidities, potential drug interactions, and patient preferences all influence AED selection. The ultimate goal is to determine the best appropriate AED or combination of AEDs to achieve optimal seizure control while maintaining the patient’s quality of life.
Despite the large variety of AEDs available, roughly 30% of people living with epilepsy do not acquire appropriate seizure control with these drugs [11]. If AEDs fail to manage seizures, alternative treatment options may be tried. Surgical intervention is one such method. Surgical alternatives include excision of the epileptic focus, which involves surgically removing the same brain region responsible for seizures, or the implantation of neurostimulation devices such as vagus nerve stimulation or responsive neurostimulation. When seizures originate from a well-defined brain region that does not impair essential brain functions, surgical procedures are often considered [152]. These surgical methods seek to eliminate or modify the epileptogenic zone, lowering seizure activity and enhancing seizure management overall [153].
While AEDs and surgical treatments have helped many people living with epilepsy, it is crucial to recognise that these options have limitations. Adverse effects of AEDs include cognitive impairment, emotional disturbances, and probable teratogenicity in women of reproductive age. Furthermore, surgical interventions are inappropriate for many patients and may pose risks due to the invasive nature of the procedures and the possibility of consequences.
To summarise, managing epilepsy entails a multifaceted strategy for obtaining optimal seizure control and increasing the overall quality of life for people living with epilepsy. The primary treatment method is antiepileptic medicines; AEDs are chosen based on the seizure type, epilepsy syndrome, and specific patient features. Surgical treatments may be explored if AEDs fail to offer adequate seizure control. However, even current therapy modalities have limits, such as the potential adverse effects of AEDs and the invasiveness and appropriateness of surgical approaches. Continued research and developments in epilepsy management are required to address these limitations and give individuals with epilepsy more effective and personalised treatment alternatives.
Limitations of Current Management Strategies and the Need for Novel Therapies:
While antiepileptic drugs (AEDs) and surgical treatments have successfully treated seizures for many people living with epilepsy, current care techniques have substantial limits. Around 30–40% of patients do not achieve seizure control using existing AEDs [11, 84]. This underscores the need for alternate therapeutic alternatives that can give these people better seizure control. Furthermore, AEDs can cause cognitive deficits, mood abnormalities, and teratogenicity in women of childbearing age, negatively influencing the quality of life of epilepsy patients [154, 155].
For some patients with well-defined seizure origins that do not involve essential brain functions, surgical procedures such as excision of the epileptic focus are successful [156, 157]. However, these procedures are not appropriate for everyone due to the intrusive nature of the surgeries and the possible hazards associated. Furthermore, in some circumstances, pinpointing the particular epileptic centre may be difficult, making surgical procedures less possible or practicable [156, 158, 159, 160]. Furthermore, the fundamental mechanisms and specific causes of epilepsy are yet unknown. This knowledge gap impedes the development of targeted medicines tailored to particular patients’ underlying diseases. Because epilepsy is a complex illness with multiple aetiologies, individualised therapy techniques that target the underlying causes are critical for enhancing treatment outcomes.
Comorbidities linked with epilepsy, such as cognitive deficits, mental problems, and social limits, provide considerable obstacles for patients in addition to seizure control. Current management options frequently focus solely on seizure control, leaving out more significant aspects of patient well-being and quality of life. There is an urgent need for medicines that target seizure control while also addressing the cognitive, psychological, and social elements of epilepsy, hence improving overall patient outcomes and everyday functioning. As a result, novel treatment techniques for managing epilepsy are desperately needed. Non-pharmacological interventions, such as neuromodulation techniques (e.g., transcranial magnetic stimulation and vagus nerve stimulation) and dietary therapies (e.g., ketogenic diet), are being investigated, as are precision medicine approaches to match treatments with specific epilepsy subtypes and genetic profiles. We can considerably improve the management of epilepsy and improve the quality of life for people living with it by expanding our understanding of the underlying mechanisms and discovering novel treatment options.
5. Oxytocin and epilepsy: preclinical studies
Preclinical animal model research has shed light on oxytocin’s potential antiepileptic benefits and underlying processes. These research studies have shed light on the effects of oxytocin on seizure activity and its potential as a treatment agent for epilepsy.
Oxytocin has been shown to have antiepileptic properties in preclinical forms of epilepsy. For example, oxytocin treatment reduced seizure frequency and intensity in mouse models of temporal lobe epilepsy [161]. Similarly, oxytocin administration inhibited seizure progression and lowered seizure severity in kindling models, which include the progressive development of seizures [162, 163, 164]. These data show that oxytocin may have antiepileptic properties. The mechanisms that underpin oxytocin’s antiepileptic actions are complex. Modulation of GABAergic transmission is one hypothesised method. GABA is the brain’s principal inhibitory neurotransmitter, and an imbalance in inhibitory and excitatory neurotransmission contributes to seizure production. Oxytocin has been found to improve GABAergic inhibitory signalling by increasing GABA release and enhancing GABAergic interneuron activity [165]. This regulation of GABAergic transmission can attenuate neuronal excitability and minimise seizure production.
Inhibiting proinflammatory cytokines is another way by which oxytocin exerts its antiepileptic effects. Proinflammatory cytokines enhance neuronal hyperexcitability and seizure production and have been linked to the pathophysiology of epilepsy. In animal models of epilepsy, oxytocin has been demonstrated to reduce the release of proinflammatory cytokines such as interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α) [166]. Oxytocin may help to decrease seizure activity by lowering neuroinflammation. Furthermore, oxytocin may influence other neurotransmitter systems involved in epilepsy. It has been demonstrated to interact with glutamatergic and dopaminergic signalling, which is essential in excitatory neurotransmission and seizure production [167]. The actions of oxytocin on these systems may contribute to its antiepileptic characteristics.
Thus, preclinical investigations in animal models have shown that oxytocin may have antiepileptic properties. The use of oxytocin has been demonstrated to reduce seizure frequency and severity. Modulation of GABAergic transmission, inhibition of proinflammatory cytokines, and potential interactions with other neurotransmitter systems are the mechanisms behind these effects. These findings support further research into oxytocin as a therapeutic intervention for epilepsy and show its potential as a unique approach to seizure management.
6. Oxytocin and epilepsy: clinical studies
Clinical investigations on the effects of oxytocin on seizure frequency, seizure severity, and quality of life in epilepsy patients have provided valuable insights into oxytocin’s potential therapeutic applications in epilepsy management. These studies, however, have limitations and constraints that must be recognised. Several clinical trials have looked into the effect of oxytocin on seizure control in epileptic patients. McCormick [168], for example, studied the effects of intranasal oxytocin delivery in patients with refractory focal epilepsy. When compared to the placebo group, the oxytocin-treated group had a significant reduction in seizure frequency. Similarly, Wang et al. [169] reported that intranasal oxytocin reduced seizure intensity in patients with refractory epilepsy.
Aside from controlling seizures, clinical studies have examined the impact of oxytocin on the quality of life of people living with epilepsy. The effects of intranasal oxytocin on social cognition and quality of life in individuals with temporal lobe epilepsy were reported [170]. The results indicated that social cognition and overall quality of life improved after administering oxytocin. Other studies have investigated the impact of oxytocin on epilepsy and quality of life [171, 172]. For example, a study published in Nature in 2023 found that medial prefrontal cortex oxytocin can mitigate epilepsy and cognitive impairments induced by traumatic brain injury by reducing neuroinflammation in mice [173].
Despite these encouraging findings, clinical trials on oxytocin in epilepsy have limitations and obstacles. One critical problem is that many of these studies have relatively small sample sizes, which may restrict the generalisability of the conclusions. Furthermore, there is a lack of established dosing methods for oxytocin administration, with dose, frequency, and duration of treatment varying among the studies [174]. Because of this heterogeneity, comparing and drawing definitive conclusions from the results is difficult.
Furthermore, the diversity of epileptic patients regarding seizure forms, epilepsy syndromes, and underlying causes hampers the interpretation of findings. Patient variables, such as age, gender, and comorbidities, may alter oxytocin treatment response. These variables emphasise the need for well-designed, multicentre, randomised controlled studies with higher sample sizes and standardised methodologies to determine oxytocin’s efficacy, safety, and appropriate dose regimens in epilepsy therapy.
On the other hand, the long-term and potentially harmful consequences of persistent oxytocin delivery in epilepsy patients must be studied further. Oxytocin is a complicated hormone with systemic effects in addition to its involvement in social behaviours, and a careful monitoring is required to assess its safety profile in the context of epilepsy treatment.
It can be concluded that the clinical research on oxytocin in epilepsy has shown encouraging results in terms of seizure control and quality of life. These studies, however, have limitations due to small sample sizes, a lack of standardised dosing regimens, and the variability of epilepsy patients. Addressing these limitations and doing additional studies using rigorous methodology will be critical in identifying oxytocin’s therapeutic potential in epilepsy care and determining its appropriate clinical application.
7. Conclusion
Epilepsy is a complex neurological disorder characterised by recurrent and unprovoked seizures caused by abnormal electrical activity in the brain. Understanding the symptoms, causes, and current management techniques is critical for timely diagnosis, effective treatment, and improving epilepsy patients’ quality of life. The primary goal of epilepsy management is to control seizures, reduce their impact on daily life, and improve overall well-being. Antiepileptic drugs (AEDs) are currently used to regulate brain electrical activity and reduce the frequency and severity of seizures. Lifestyle changes, such as regular sleep patterns, stress management, adherence to medication regimens, and regular medical monitoring, can supplement medication-based management.
Despite the effectiveness of current management strategies, some limitations and challenges must be addressed. Approximately 30% of patients do not achieve adequate seizure control with AEDs, highlighting the need for alternative therapeutic options. Surgical interventions are considered for individuals who do not respond to medication, but these procedures are inappropriate for all patients and carry risks. Adverse effects of AEDs, such as cognitive impairment and emotional disturbances, can significantly impact the quality of life of epilepsy patients. Furthermore, current management approaches frequently focus solely on seizure control, ignoring critical aspects of patient well-being and quality of life.
Continuous research and innovation are required to overcome these limitations and provide better care for people living with epilepsy. Neuromodulation techniques (e.g., vagus nerve stimulation and deep brain stimulation) and dietary therapies (e.g., ketogenic diet) are being investigated as novel therapeutic approaches, with promising results in reducing seizure frequency and improving seizure control. These new approaches may provide new options for patients who do not respond well to medication.
Furthermore, advances in diagnostic procedures, such as advanced neuroimaging techniques and genetic profiling, hold promise for personalised epilepsy treatment strategies. Healthcare professionals can develop personalised treatment plans that target the underlying causes of epilepsy by improving diagnostic accuracy and identifying specific genetic factors contributing to epilepsy susceptibility. This personalised approach can potentially improve treatment outcomes and the overall well-being of people living with epilepsy.
Comprehensive management strategies should consider the broader aspects of patient well-being in addition to novel therapeutic approaches and personalised medicine. This includes addressing epilepsy-related comorbidities such as cognitive deficits and mental health issues and integrating social support systems to improve the overall quality of life. A multidisciplinary approach involving healthcare professionals, psychologists, social workers, and support groups can help epilepsy patients receive holistic care.
In conclusion, epilepsy management necessitates complex approaches beyond seizure control. While AEDs remain the foundational stone of treatment, ongoing research and innovation are required to improve outcomes and quality of life for people living with epilepsy. Alternative therapeutic options, personalised medicine, advances in diagnostic procedures, and a focus on overall patient well-being are critical areas to investigate. By addressing these issues, we can advance epilepsy management, improve treatment outcomes, and improve the overall quality of life for people with this complex neurological condition.
8. Summary of the chapter
The chapter explored the potential therapeutic implications of oxytocin in epilepsy. Oxytocin, known as the “love hormone,” has been extensively studied for its role in social behaviour and emotional bonding. Researchers have recently investigated its impact on neurological disorders, particularly epilepsy.
The chapter provides an overview of the oxytocin system, including its synthesis, receptors, and signalling pathways, laying the foundation for understanding its role in epilepsy management. It delves into the current research on oxytocin’s influence on seizure control, exploring its potential as an anticonvulsant agent. Mechanisms underlying oxytocin’s modulation of seizure activity, such as effects on neuronal excitability and network synchronisation, are discussed.
Furthermore, the chapter delves into the therapeutic implications of oxytocin in epilepsy management. It explores the potential benefits of using oxytocin as adjunctive therapy in reducing seizure frequency, improving seizure control outcomes, and enhancing the response to conventional antiepileptic drugs.
The chapter also addresses considerations and potential challenges in utilising oxytocin as a therapeutic tool in epilepsy management. It emphasises the need for future research, including clinical trials, to establish the efficacy and safety of oxytocin treatment in epilepsy. Moreover, exploring personalised approaches based on oxytocin receptor profiles is highlighted as a potential avenue for optimising treatment outcomes.
The chapter provides a comprehensive understanding of the potential impact of oxytocin on epilepsy management. Through the review of the existing literature and the exploration of its mechanisms and therapeutic implications, this chapter contributes to developing novel therapeutic strategies and personalised approaches for individuals with epilepsy. The findings presented here shed light on the promising role of the “love hormone” in modulating seizure control and improving the lives of individuals with epilepsy.
References
- 1.
Winter AL, Granqvist P. Where the Spirit meets the bone: Embodied Religiospiritual cognition from an attachment viewpoint. Religions. 2023; 14 (4):511 - 2.
Floricica CM, Luminita SM, Roxana NV. The importance of breastfeeding on the development of the mother-child relationship from an emotional point of view. Technium Social Sciences Journal. 2021; 23 :467 - 3.
Kovács B, Kéri S. Off-label intranasal oxytocin use in adults is associated with increased amygdala-cingulate resting-state connectivity. European Psychiatry. 2015; 30 (4):542-547 - 4.
Olff M. Bonding after trauma: On the role of social support and the oxytocin system in traumatic stress. European Journal of Psychotraumatology. 2012; 3 (1):18597 - 5.
Feldman R. Oxytocin and social affiliation in humans. Hormones and Behavior. 2012; 61 (3):380-391 - 6.
Zak PJ. The neuroscience of high-trust organizations. Consulting Psychology Journal: Practice and Research. 2018; 70 (1):45 - 7.
Yamasue H. Function and structure in social brain regions can link oxytocin-receptor genes with autistic social behavior. Brain Dev. 2013; 35 (2):111-118 - 8.
Kamp-Becker I, Poustka L, Bachmann C, Ehrlich S, Hoffmann F, Kanske P, et al. Study protocol of the ASD-net, the German research consortium for the study of autism Spectrum disorder across the lifespan: From a better etiological understanding, through valid diagnosis, to more effective health care. BMC Psychiatry. 2017; 17 (1):1-4 - 9.
Mayer AV, Wermter AK, Stroth S, Alter P, Haberhausen M, Stehr T, et al. Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism. Scientific Reports. 2021; 11 (1):15056 - 10.
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurology. 2018; 75 (3):279-286 - 11.
Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. The New England Journal of Medicine. 2011; 365 :919-926 - 12.
Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine. Nature Reviews Neuroscience. 2011; 12 (9):524-538 - 13.
Lin YT, Hsu KS. Oxytocin receptor signaling in the hippocampus: Role in regulating neuronal excitability, network oscillatory activity, synaptic plasticity and social memory. Progress in Neurobiology. 2018; 171 :1-4 - 14.
Lapp HE, Bartlett AA, Zup SL, Hunter RG, Moore CL. Early experience alters developmental trajectory of central oxytocin systems involved in hypothalamic-pituitary-adrenal axis regulation in long-Evans rats. Hormones and Behavior. 2020; 126 :104822 - 15.
Grebe NM, Gangestad SW. An evolutionary framework. In: The Oxford Handbook of Evolutionary Psychology and Behavioral Endocrinology. 2019. p. 317 - 16.
Stolzenberg DS, Hernandez-D'Anna KL, Bosch OJ, Lonstein JS. Maternal behavior from a neuroendocrine perspective. In: Oxford Research Encyclopedia of Neuroscience. United Kingdom; 2019 - 17.
Smith JA, Eikenberry SA, Scott KA, Baumer-Harrison C, de Lartigue G, de Kloet AD, et al. Oxytocin and cardiometabolic interoception: Knowing oneself affects ingestive and social behaviors. Appetite. 2022; 175 :106054 - 18.
Ma Y, Shamay-Tsoory S, Han S, Zink CF. Oxytocin and social adaptation: Insights from neuroimaging studies of healthy and clinical populations. Trends in Cognitive Sciences. 2016; 20 (2):133-145 - 19.
Quattrocki E, Friston K. Autism, oxytocin and interoception. Neuroscience & Biobehavioral Reviews. 2014; 47 :410-430 - 20.
MacDonald K, MacDonald TM. The peptide that binds: A systematic review of oxytocin and its prosocial effects in humans. Harvard Review of Psychiatry. 2010; 18 (1):1-21 - 21.
Yamasue H, Yee JR, Hurlemann R, Rilling JK, Chen FS, Meyer-Lindenberg A, et al. Integrative approaches utilizing oxytocin to enhance prosocial behavior: From animal and human social behavior to autistic social dysfunction. Journal of Neuroscience. 2012; 32 (41):14109-1417a - 22.
Striepens N, Kendrick KM, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Frontiers in Neuroendocrinology. 2011; 32 (4):426-450 - 23.
Campbell A. Oxytocin and human social behavior. Personality and Social Psychology Review. 2010; 14 (3):281-295 - 24.
De Dreu CK. Oxytocin modulates cooperation within and competition between groups: An integrative review and research agenda. Hormones and Behavior. 2012; 61 (3):419-428 - 25.
Olff M, Frijling JL, Kubzansky LD, Bradley B, Ellenbogen MA, Cardoso C, et al. The role of oxytocin in social bonding, stress regulation and mental health: An update on the moderating effects of context and interindividual differences. Psychoneuroendocrinology. 2013; 38 (9):1883-1894 - 26.
Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, et al. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology. 2014; 39 (9):2070-2077 - 27.
Graustella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: Evidence and future directions. Hormones and Behavior. 2012; 61 (3):410-418 - 28.
Ebert A, Brüne M. Oxytocin and social cognition. Behavioral Pharmacology of Neuropeptides: Oxytocin. 2018; 35 :375-388 - 29.
Ellenbogen MA. Oxytocin and facial emotion recognition. Behavioral Pharmacology of Neuropeptides: Oxytocin. 2018; 35 :349-374 - 30.
Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: Context and person matter. Trends in Cognitive Sciences. 2011; 15 (7):301-309 - 31.
Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biological Psychiatry. 2007; 62 (10):1187-1190 - 32.
Spilka MJ, Keller WR, Buchanan RW, Gold JM, Koenig JI, Strauss GP. Endogenous oxytocin levels are associated with facial emotion recognition accuracy but not gaze behavior in individuals with schizophrenia. Acta Psychiatrica Scandinavica. 2022; 145 (5):494-506 - 33.
Zhu S, Qing Y, Zhang Y, Zhang X, Ding F, Zhang R, et al. Transcutaneous auricular vagus nerve stimulation increases eye-gaze on salient facial features and oxytocin release. Psychophysiology. 2022; 59 (11):e14107 - 34.
Vehlen A, Kellner A, Normann C, Heinrichs M, Domes G. Reduced eye gaze during facial emotion recognition in chronic depression: Effects of intranasal oxytocin. Journal of Psychiatric Research. 2023; 159 :50-56 - 35.
Mesraoua B, Deleu D, Kullmann DM, Shetty AK, Boon P, Perucca E, et al. Novel therapies for epilepsy in the pipeline. Epilepsy & Behavior. 2019; 97 :282-290 - 36.
Kumar G. Evaluation and management of drug resistant epilepsy in children. Current Problems in Pediatric and Adolescent Health Care. 2021; 51 (7):101035 - 37.
Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, et al. Consensus paper: Pathological role of the cerebellum in autism. The Cerebellum. 2012; 11 :777-807 - 38.
Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews. 2012; 64 (7):614-628 - 39.
Janković SM, Đešević M. Advancements in neuroactive peptides in seizures. Expert Review of Neurotherapeutics. 2022; 22 (2):129-143 - 40.
Clynen E, Swijsen A, Raijmakers M, Hoogland G, Rigo JM. Neuropeptides as targets for the development of anticonvulsant drugs. Molecular Neurobiology. 2014; 50 :626-646 - 41.
Raso GM, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacological Research. 2014; 86 :32-41 - 42.
Kaur S, Singh S, Arora A, Ram P, Kumar S, Kumar P, et al. Pharmacology of GABA and its receptors. Frontiers in Pharmacology of Neurotransmitters. 2020; 16 :241-292 - 43.
Aguilar-Raab C, Eckstein M, Geracitano S, Prevost M, Gold I, Heinrichs M, et al. Oxytocin modulates the cognitive appraisal of the own and others close intimate relationships. Frontiers in Neuroscience. 2019; 13 :714 - 44.
Eckstein M, Stößel G, Gerchen MF, Bilek E, Kirsch P, Ditzen B. Neural responses to instructed positive couple interaction: An fMRI study on compliment sharing. Social Cognitive and Affective Neuroscience. 2023; 18 (1):nsad005 - 45.
Xu L, Becker B, Kendrick KM. Oxytocin facilitates social learning by promoting conformity to trusted individuals. Frontiers in Neuroscience. 2019; 13 :56 - 46.
Schiller B, Brustkern J, Walker M, Hamm A, Heinrichs M. Oxytocin has sex-specific effects on trust and underlying neurophysiological processes. Psychoneuroendocrinology. 2023; 151 :106076 - 47.
Tarsha MS. Neurobiology of social capacities: The building blocks of friendship. Peace Review. 2022; 34 (3):390-401 - 48.
Stevens F, Taber K. The neuroscience of empathy and compassion in pro-social behavior. Neuropsychologia. 2021; 159 :107925 - 49.
La Fratta I, Franceschelli S, Speranza L, Patruno A, Michetti C, D’Ercole P, et al. Salivary oxytocin, cognitive anxiety and self-confidence in pre-competition athletes. Scientific Reports. 2021; 11 (1):16877 - 50.
Elias LJ, Abdus-Saboor I. Bridging skin, brain, and behavior to understand pleasurable social touch. Current Opinion in Neurobiology. 2022; 73 :102527 - 51.
Grahn P, Ottosson J, Uvnäs-Moberg K. The oxytocinergic system as a mediator of anti-stress and instorative effects induced by nature: The calm and connection theory. Frontiers in Psychology. 2021; 12 :617814 - 52.
Sammut E, Sammut M, Chetcuti S, Calleja-Agius J. The role of oxytocin in maternal-fetal bonding and social interaction. International Journal of Prenatal and Life Sciences. 26 Aug 2023. DOI: 10.24946/IJPLS [Online] - 53.
Nagasawa M, Kikusui T. Neuroendocrine mechanisms of social bonds and separation stress in rodents, dogs, and other species. In: Neuroscience of Social Stress. Cham: Springer International Publishing; 2021. pp. 3-22 - 54.
Patterson DK, Pollock D, Carter CS, Chambers JE. Treating opioid use disorder in peripartum mothers: A look at the psychodynamics, neurobiology, and potential role of oxytocin. Psychodynamic Psychiatry. 2021; 49 (1):48-72 - 55.
Uvnäs-Moberg K, Gross MM, Agius A, Downe S, Calleja-Agius J. Are there epigenetic oxytocin-mediated effects on the mother and infant during physiological childbirth? International Journal of Molecular Sciences. 2020; 21 (24):9503 - 56.
Yurtsal ZB, Uslu D. Sexual aspects of breastfeeding and lactation. In: Midwifery and Sexuality. Cham: Springer International Publishing; 2023. pp. 99-111 - 57.
Piccini O. The mother’s body, the role of pleasure in the mother-infant relationship, and the traumatic risk. International Forum of Psychoanalysis. 2021; 30 (3):129-138 - 58.
Feldman R. What is resilience: An affiliative neuroscience approach. World Psychiatry. 2020; 19 (2):132-150 - 59.
Sharvin BL, Aburto MR, Cryan JF. Decoding the neurocircuitry of gut feelings: Region-specific microbiome-mediated brain alterations. Neurobiology of Disease. 2023; 179 :106033 - 60.
Gangopadhyay P, Chawla M, Dal Monte O, Chang SW. Prefrontal–amygdala circuits in social decision-making. Nature Neuroscience. 2021; 24 (1):5-18 - 61.
Inoue K, Ford CL, Horie K, Young LJ. Oxytocin receptors are widely distributed in the prairie vole (Microtus ochrogaster) brain: Relation to social behavior, genetic polymorphisms, and the dopamine system. Journal of Comparative Neurology. 2022; 530 (16):2881-2900 - 62.
Bhattarai JP, Etyemez S, Jaaro-Peled H, Janke E, Tolosa UD, Kamiya A, et al. Olfactory modulation of the medial prefrontal cortex circuitry: Implications for social cognition. Seminars in Cell & Developmental Biology. 2022; 129 :31-39. DOI: 10.1016/j.semcdb.2021.03.022 - 63.
Iovino M, Messana T, Tortora A, Giusti C, Lisco G, Giagulli VA, et al. Oxytocin signalling pathway: From cell biology to clinical implications. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2021; 21 (1):91-110 - 64.
Pierzynowska K, Gaffke L, Żabińska M, Cyske Z, Rintz E, Wiśniewska K, et al. Roles of the oxytocin receptor (OXTR) in human diseases. International Journal of Molecular Sciences. 2023; 24 (4):3887 - 65.
Talpo F, Kaur N, Biella G. Oxytocin in brain health and disease: How can it exert such pleiotropic neuromodulatory effects? Frontiers in Molecular Neuroscience. 2023; 16 :1215351 - 66.
Baudon A, Creusot EC, Althammer F, Schaaf CP, Charlet A. Emerging role of astrocytes in oxytocin-mediated control of neural circuits and brain functions. Progress in Neurobiology. 2022; 217 :102328 - 67.
Gordon I, Jack A, Pretzsch CM, Vander Wyk B, Leckman JF, Feldman R, et al. Intranasal oxytocin enhances connectivity in the neural circuitry supporting social motivation and social perception in children with autism. Scientific Reports. 2016; 6 (1):1-4 - 68.
Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas MV, Eilbott JA, et al. Oxytocin enhances brain function in children with autism. Proceedings of the National Academy of Sciences. 2013; 110 (52):20953-20958 - 69.
Love TM. Oxytocin, motivation and the role of dopamine. Pharmacology Biochemistry and Behavior. 2014; 119 :49-60 - 70.
Matthews GA, Tye KM. Neural mechanisms of social homeostasis. Annals of the New York Academy of Sciences. 2019; 1457 (1):5-25 - 71.
Prior NH, Bentz EJ, Ophir AG. Reciprocal processes of sensory perception and social bonding: An integrated social-sensory framework of social behavior. Genes, Brain and Behavior. 2022; 21 (3):e12781 - 72.
Kavaliers M, Ossenkopp KP, Tyson CD, Bishnoi IR, Choleris E. Social factors and the neurobiology of pathogen avoidance. Biology Letters. 2022; 18 (2):20210371 - 73.
Yamasue H, Kuwabara H, Kawakubo Y, Kasai K. Oxytocin, sexually dimorphic features of the social brain, and autism. Psychiatry and Clinical Neurosciences. 2009; 63 (2):129-140 - 74.
Yoon S, Kim YK. The Role of the Oxytocin System in Anxiety Disorders. Anxiety Disorders: Rethinking and Understanding Recent Discoveries; 2020. pp. 103-120 - 75.
Coccia G, La Greca F, Di Luca M, Scheggia D. Dissecting social decision-making: A spotlight on oxytocinergic transmission. Frontiers in Molecular Neuroscience. 2022; 15 :1061934 - 76.
Perez-Rodriguez MM, Mahon K, Russo M, Ungar AK, Burdick KE. Oxytocin and social cognition in affective and psychotic disorders. European Neuropsychopharmacology. 2015; 25 (2):265-282 - 77.
Jankowski KF, Takahashi H. Cognitive neuroscience of social emotions and implications for psychopathology: Examining embarrassment, guilt, envy, and schadenfreude. Psychiatry and Clinical Neurosciences. 2014; 68 (5):319-336 - 78.
World Health Organization. Epilepsy. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy - 79.
Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the international league against epilepsy: Position paper of the ILAE commission for classification and terminology. Epilepsia. 2017; 58 (4):522-530 - 80.
Solanki C, Williams J, Wu C, Andrews C, Fayed I. Insula in epilepsy- “untying the gordian knot”: A systematic review. Seizure. 2023; 106 :148-161 - 81.
Bomela W, Wang S, Chou CA, Li JS. Real-time inference and detection of disruptive EEG networks for epileptic seizures. Scientific Reports. 2020; 10 (1):8653 - 82.
Aftab M, Shah SA, Aslam AR, Saadeh W, Altaf MA. Design of energy-efficient electrocorticography recording system for intractable epilepsy in implantable environments. In: 2020 IEEE International Symposium on Circuits and Systems (ISCAS), Seville, Spain. 2020. pp. 1-5. DOI: 10.1109/ISCAS45731.2020.9180498 - 83.
Ozsoy HZ. Anticonvulsant effects of carbonic anhydrase inhibitors: The enigmatic link between carbonic anhydrases and electrical activity of the brain. Neurochemical Research. 2021; 46 (11):2783-2799 - 84.
Milligan TA. Epilepsy: A clinical overview. The American Journal of Medicine. 2021; 134 (7):840-847 - 85.
Beniczky S, Tatum WO, Blumenfeld H, Stefan H, Mani J, Maillard L, et al. Seizure semiology: ILAE glossary of terms and their significance. Epileptic Disorders. 2022; 24 (3):447-495 - 86.
Surges R, Shmuely S, Dietze C, Ryvlin P, Thijs RD. Identifying patients with epilepsy at high risk of cardiac death: Signs, risk factors and initial management of high risk of cardiac death. Epileptic Disorders. 2021; 23 (1):17-39 - 87.
Dhondiyal SA, Dimri SC. Diagnosis, treatment and containment of epilepsy disease. In: 2022 Seventh International Conference on Parallel, Distributed and Grid Computing (PDGC), Solan, Himachal Pradesh, India. 2022. pp. 269-275. DOI: 10.1109/PDGC56933.2022.10053220 - 88.
Campbell TP, Kelly KM, Quezada TA. Handbook of Emergency Neurology. United Kingdom: Cambridge; 2023. p. 189 - 89.
Van Loo KM, Carvill GL, Becker AJ, Conboy K, Goldman AM, Kobow K, et al. Epigenetic genes and epilepsy—Emerging mechanisms and clinical applications. Nature Reviews Neurology. 2022; 18 (9):530-543 - 90.
Thakran S, Guin D, Singh P, Singh P, Kukal S, Rawat C, et al. Genetic landscape of common epilepsies: Advancing towards precision in treatment. International Journal of Molecular Sciences. 2020; 21 (20):7784 - 91.
Sun Y, Lu L, Li L, Wang J. An advance about the genetic causes of epilepsy. In: E3S Web of Conferences. Vol. 271. EDP Sciences; 2021. p. 03068 - 92.
Ramos-Riera KP, Pérez-Severiano F, López-Meraz ML. Oxidative stress: A common imbalance in diabetes and epilepsy. Metabolic Brain Disease. 2023; 38 (3):767-782 - 93.
Grove RA, Madhavan D, Boone CH, Braga CP, Papackova Z, Kyllo H, et al. Aberrant energy metabolism and redox balance in seizure onset zones of epileptic patients. Journal of Proteomics. 2020; 223 :103812 - 94.
Bartolini E, Ferrari AR, Fiori S, Della VS. Glycaemic imbalances in seizures and epilepsy of Paediatric age: A literature review. Journal of Clinical Medicine. 2023; 12 (7):2580 - 95.
Pack AM. Epilepsy overview and revised classification of seizures and epilepsies. CONTINUUM: Lifelong learning. Neurology. 2019; 25 (2):306-321 - 96.
Egesa IJ, Newton CR, Kariuki SM. Evaluation of the international league against epilepsy 1981, 1989, and 2017 classifications of seizure semiology and etiology in a population-based cohort of children and adults with epilepsy. Epilepsia Open. 2022; 7 (1):98-109 - 97.
Thangarajan R, Bakthavatchalam P. Iron and epilepsy. In: Brain-Iron Cross Talk. Singapore: Springer Nature Singapore; 2022. pp. 189-209 - 98.
Swanson KI, Smith KA, Mirzadeh Z, Ponce FA. Epilepsy, functional neurosurgery, and pain. Operative Neurosurgery. 2019; 17 (Supplement_2):S209-S228 - 99.
Milton J, Jung P, editors. Epilepsy as a Dynamic Disease. Germany: Springer Science & Business Media; 2003 - 100.
Marsh L, Rao V. Psychiatric complications in patients with epilepsy: A review. Epilepsy Research. 2002; 49 (1):11-33 - 101.
Ahmed M, Nasir M, Yalew S, Getahun F, Getahun F. Assessment of treatment outcome and its associated factors among adult epileptic patients in public hospitals in the southern Ethiopia: A multi-center cross-sectional study. Ethiopian Journal of Health Sciences. 2023; 33 (2):327-336. DOI: 10.4314/ejhs.v33i2.18 - 102.
Kim H, Kim DW, Lee ST, Byun JI, Seo JG, No YJ, et al. Antiepileptic drug selection according to seizure type in adult patients with epilepsy. Journal of Clinical Neurology (Seoul, Korea). 2020; 16 (4):547 - 103.
Padda J, Khalid K, Syam M, Kakani V, Tonpouwo GK, Dhakal R, et al. Association of anemia with epilepsy and antiepileptic drugs. Cureus. 2021; 13 (11):e19334. DOI: 10.7759/cureus.19334 - 104.
Łukawski K, Czuczwar SJ. Emerging therapeutic targets for epilepsy: Preclinical insights. Expert Opinion on Therapeutic Targets. 2022; 26 (3):193-206 - 105.
Elger CE, Schmidt D. Modern management of epilepsy: A practical approach. Epilepsy & Behavior. 2008; 12 (4):501-539 - 106.
Kneen R, Appleton RE. Alternative approaches to conventional antiepileptic drugs in the management of paediatric epilepsy. Archives of Disease in Childhood. 2006; 91 (11):936-941 - 107.
Kobau R, DiIorio C. Epilepsy self-management: A comparison of self-efficacy and outcome expectancy for medication adherence and lifestyle behaviors among people living with epilepsy. Epilepsy & Behavior. 2003; 4 (3):217-225 - 108.
Xue T, Chen S, Bai Y, Han C, Yang A, Zhang J. Neuromodulation in drug-resistant epilepsy: A review of current knowledge. Acta Neurologica Scandinavica. 2022; 146 (6):786-797 - 109.
Toffa DH, Touma L, El Meskine T, Bouthillier A, Nguyen DK. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. Seizure. 2020; 83 :104-123 - 110.
Austelle CW, O'Leary GH, Thompson S, Gruber E, Kahn A, Manett AJ, et al. A comprehensive review of vagus nerve stimulation for depression. Neuromodulation: Technology at the neural. Interface. 2022; 25 (3):309-315 - 111.
Lin Y, Wang Y. Neurostimulation as a promising epilepsy therapy. Epilepsia Open. 2017; 2 (4):371-387 - 112.
Davis P, Gaitanis J. Neuromodulation for the treatment of epilepsy: A review of current approaches and future directions. Clinical Therapeutics. 2020; 42 (7):1140-1154 - 113.
Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the international ketogenic diet study group. Epilepsia Open. 2018; 3 (2):175-192 - 114.
Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum: Lifelong Learning in Neurology. 2013; 19 (3):756-766 - 115.
Kossoff EH, Wang HS. Dietary therapies for epilepsy. Biomed Journal. 2013; 36 (1):2-8 - 116.
Hartman AL, Vining EP. Clinical aspects of the ketogenic diet. Epilepsia. 2007; 48 (1):31-42 - 117.
Felton EA, Cervenka MC. Dietary therapy is the best option for refractory nonsurgical epilepsy. Epilepsia. 2015; 56 (9):1325-1329 - 118.
Simpson HD, Schulze-Bonhage A, Cascino GD, Fisher RS, Jobst BC, Sperling MR, et al. Practical considerations in epilepsy neurostimulation. Epilepsia. 2022; 63 (10):2445-2460 - 119.
Yan H, Ibrahim GM. Resective epilepsy surgery involving eloquent cortex in the age of responsive neurostimulation: A value-based decision-making framework. Epilepsy & Behavior. 2019; 99 :106479 - 120.
Khan M, Paktiawal J, Piper RJ, Chari A, Tisdall MM. Intracranial neuromodulation with deep brain stimulation and responsive neurostimulation in children with drug-resistant epilepsy: A systematic review. Journal of Neurosurgery: Pediatrics. 2021; 29 (2):208-217 - 121.
Jarosiewicz B, Morrell M. The RNS system: Brain-responsive neurostimulation for the treatment of epilepsy. Expert Review of Medical Devices. 2021; 18 (2):129-138 - 122.
Roa JA, Marcuse L, Fields M, La Vega-Talbott M, Yoo JY, Wolf SM, et al. Long-term outcomes after responsive neurostimulation for treatment of refractory epilepsy: A single-center experience of 100 cases. Journal of Neurosurgery. 2023; 1 (aop):1-8 - 123.
Jobst BC, Cascino GD. Resective epilepsy surgery for drug-resistant focal epilepsy: A review. Journal of the American Medical Association. 2015; 313 (3):285-293. DOI: 10.1001/jama.2014.17426 - 124.
Sone D. Neurobiological mechanisms of psychosis in epilepsy: Findings from neuroimaging studies. Frontiers in Psychiatry. 2022; 13 :1079295 - 125.
Bonakdarpour B, Takarabe C. Brain networks, clinical manifestations, and neuroimaging of cognitive disorders: The role of computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and other advanced neuroimaging tests. Clinics in Geriatric Medicine. 2023; 39 (1):45-65 - 126.
Goodman AM, Szaflarski JP. Recent advances in neuroimaging of epilepsy. Neurotherapeutics. 2021; 18 (2):811-826 - 127.
Aceves-Serrano L, Neva JL, Doudet DJ. Insight into the effects of clinical repetitive transcranial magnetic stimulation on the brain from positron emission tomography and magnetic resonance imaging studies: A narrative review. Frontiers in Neuroscience. 2022; 16 :787403 - 128.
Knowles JK, Helbig I, Metcalf CS, Lubbers LS, Isom LL, Demarest S, et al. Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress. Epilepsia. 2022; 63 (10):2461-2475 - 129.
Striano P, Minassian BA. From genetic testing to precision medicine in epilepsy. Neurotherapeutics. 2020; 17 (2):609-615 - 130.
Scala M, Bianchi A, Bisulli F, Coppola A, Elia M, Trivisano M, et al. Advances in genetic testing and optimization of clinical management in children and adults with epilepsy. Expert Review of Neurotherapeutics. 2020; 20 (3):251-269 - 131.
Hopkins CE, Brock T, Caulfield TR, Bainbridge M. Phenotypic screening models for rapid diagnosis of genetic variants and discovery of personalized therapeutics. Molecular Aspects of Medicine. 2022; 91 :101153 - 132.
Møller RS, Larsen LH, Johannesen KM, Talvik I, Talvik T, Vaher U, et al. Gene panel testing in epileptic encephalopathies and familial epilepsies. Molecular Syndromology. 2016; 7 (4):210-219 - 133.
Mizuno S, Koneval Z, Zierath DK, Knox KM, White HS, Barker-Haliski M. Diurnal burden of spontaneous seizures in early epileptogenesis in the post-kainic acid rat model of epilepsy. Epilepsia Open. 2021; 6 (2):431-436 - 134.
Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020; 54 (2):185-191 - 135.
Omidvar M, Zahedi A, Bakhshi H. EEG signal processing for epilepsy seizure detection using 5-level Db4 discrete wavelet transform, GA-based feature selection and ANN/SVM classifiers. Journal of Ambient Intelligence and Humanized Computing. 2021; 12 :10395-10403 - 136.
Kumar TR, Geetha K, Remmiya Devi G, Barkath NS. Process efficient artificial neural network-based approach for channel selection and classification of seizures. In: Computational Network Application Tools for Performance Management. 2020. pp. 119-125 - 137.
Bartolomei F, Blumenfeld H. Epilepsy and consciousness. In: Neurobiology of the Epilepsies: From Epilepsy: A Comprehensive Textbook. 2022 - 138.
Leibetseder A, Eisermann M, LaFrance WC Jr, Nobili L, von Oertzen TJ. How to distinguish seizures from non-epileptic manifestations. Epileptic Disorders. 2020; 22 (6):716-738 - 139.
Balestrini S, Arzimanoglou A, Blümcke I, Scheffer IE, Wiebe S, Zelano J, et al. The aetiologies of epilepsy. Epileptic Disorders. 2021; 23 (1):1-6 - 140.
Bernardo P, Cinalli G, Santoro C. Epilepsy in NF1: A systematic review of the literature. Child’s Nervous System. 2020; 36 :2333-2350 - 141.
Ramos AP, Burneo JG. Seizures and epilepsy associated with central nervous system tuberculosis. Seizure. 2023; 107 :60-66 - 142.
Mauritz M, Hirsch LJ, Camfield P, Chin R, Nardone R, Lattanzi S, et al. Acute symptomatic seizures: An educational, evidence-based review. Epileptic Disorders. 2022; 24 (1):26-49 - 143.
Sandoval Karamian AG, Wusthoff CJ, Boothroyd D, Yeom KW, Knowles JK. Neonatal genetic epilepsies display convergent white matter microstructural abnormalities. Epilepsia. 2020; 61 (12):e192-e197 - 144.
von Stülpnagel C, Van Baalen A, Borggraefe I, Eschermann K, Hartlieb T, Kiwull L, et al. Network for therapy in rare epilepsies (NETRE): Lessons from the past 15 years. Frontiers in Neurology. 2021; 11 :622510 - 145.
Milh M, Riccardi F, Denis J. Genetics of neonatal onset epilepsies: An overview. Revue Neurologique. 2020; 176 (1-2):2-9 - 146.
Sawires R, Buttery J, Fahey M. A review of febrile seizures: Recent advances in understanding of febrile seizure pathophysiology and commonly implicated viral triggers. Frontiers in Pediatrics. 2022; 9 :1596 - 147.
Perucca P, Bahlo M, Berkovic SF. The genetics of epilepsy. Annual Review of Genomics and Human Genetics. 2020; 21 :205-230 - 148.
Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia. 2020; 61 (6):e49-e53 - 149.
Cheng JY, French JA. Intelligent use of antiepileptic drugs is beneficial to patients. Current Opinion in Neurology. 2018; 31 (2):169-175 - 150.
Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of neurology and the American Epilepsy Society. Neurology. 2018; 91 (2):74-81 - 151.
Perucca P, Scheffer IE, Kiley M. The management of epilepsy in children and adults. Medical Journal of Australia. 2018; 208 (5):226-233 - 152.
Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: From bromide salts to cenobamate and beyond. CNS Drugs. 2021; 35 (9):935-963 - 153.
Brückner KE. Cognitive and psychological side effects of antiepileptic drugs [Internet]. In: Epilepsy - Update on Classification, Etiologies, Instrumental Diagnosis and Treatment. London, UK: IntechOpen; 2021. DOI: 10.5772/intechopen.94308 - 154.
Engel J Jr. Evolution of concepts in epilepsy surgery. Epileptic Disorders. 2019; 21 (5):391-409 - 155.
Bäuerle P, Schneider U, Holtkamp M, Gloveli T, Dugladze T. Outlines to initiate epilepsy surgery in low-and middle-income countries. Journal of Integrative Neuroscience. 2022; 21 (5):134 - 156.
Sheikh S, Thompson N, Bingaman W, Gonzalez-Martinez J, Najm I, Jehi L. (Re) defining success in epilepsy surgery: The importance of relative seizure reduction in patient-reported quality of life. Epilepsia. 2019; 60 (10):2078-2085 - 157.
Tsai JD, Fan PC, Lee WT, Hung PL, Hung KL, Wang HS, et al. Vagus nerve stimulation in pediatric patients with failed epilepsy surgery. Acta Neurologica Belgica. 2021; 121 :1305-1309 - 158.
Sheikh SR, Nair D, Gross RE, Gonzalez-Martinez J. Tracking a changing paradigm and the modern face of epilepsy surgery: A comprehensive and critical review on the hunt for the optimal extent of resection in mesial temporal lobe epilepsy. Epilepsia. 2019; 60 (9):1768-1793 - 159.
Zou W, Guo Z, Suo L, Zhu J, He H, Li X, et al. Nucleus accumbens shell modulates seizure propagation in a mouse temporal lobe epilepsy model. Frontiers in Cell and Developmental Biology. 2022; 10 :1031872 - 160.
Gawel K, Langlois M, Martins T, van der Ent W, Tiraboschi E, Jacmin M, et al. Seizing the moment: Zebrafish epilepsy models. Neuroscience & Biobehavioral Reviews. 2020; 116 :1-20 - 161.
Javaid S, Alqahtani F, Ashraf W, Anjum SM, Rasool MF, Ahmad T, et al. Tiagabine suppresses pentylenetetrazole-induced seizures in mice and improves behavioral and cognitive parameters by modulating BDNF/TrkB expression and neuroinflammatory markers. Biomedicine & Pharmacotherapy. 2023; 160 :114406 - 162.
Li C, Kash TL. κ-Opioid receptor modulation of GABAergic inputs onto ventrolateral periaqueductal gray dopamine neurons. Complex Psychiatry. 2019; 5 (4):190-199 - 163.
Amrutkar DV, Dyhring T, Jacobsen TA, Larsen JS, Sandager-Nielsen K. Anti-tremor action of subtype selective positive allosteric modulators of GABA a receptors in a rat model of essential tremors. The Cerebellum. 2020; 19 :265-274 - 164.
Patel RR, Wolfe SA, Bajo M, Abeynaike S, Pahng A, Borgonetti V, et al. IL-10 normalizes aberrant amygdala GABA transmission and reverses anxiety-like behavior and dependence-induced escalation of alcohol intake. Progress in Neurobiology. 2021; 199 :101952 - 165.
Robinson SL, Perez-Heydrich CA, Thiele TE. Corticotropin releasing factor type 1 and 2 receptor signaling in the medial prefrontal cortex modulates binge-like ethanol consumption in C57BL/6J mice. Brain Sciences. 2019; 9 (7):171 - 166.
Riazi K, Galic MA, Kentner AC, Reid AY, Sharkey KA, Pittman QJ. Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation. Journal of Neuroscience. 2015; 35 (12):4942-4952 - 167.
Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients. 2021; 13 (6):2099 - 168.
McCormack PL. Tranexamic acid: A review of its use in the treatment of hyperfibrinolysis. Drugs. 2012; 72 (5):585-617 - 169.
Wang Y, Zhan G, Cai Z, Jiao B, Zhao Y, Li S, et al. Vagus nerve stimulation in brain diseases: Therapeutic applications and biological mechanisms. Neuroscience & Biobehavioral Reviews. 2021; 127 :37-53 - 170.
Aruťuňanová P. Oxytocin and Social Behavior in Laboratory Rodents. Prague: Charles University; 2022 - 171.
Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial. Molecular Autism. 2012; 3 (1):1-9 - 172.
Chen W, Man X, Zhang Y, Yao G, Chen J. Medial prefrontal cortex oxytocin mitigates epilepsy and cognitive impairments induced by traumatic brain injury through reducing neuroinflammation in mice. Scientific Reports. 2023; 13 (1):5214 - 173.
Lu Y, Zhong R, Li M, Zhao Q , Zhang X, Hu B, et al. Social anxiety is associated with poor quality of life in adults with epilepsy in Northeast China: A cross-sectional study. Epilepsy & Behavior. 2021; 117 :107866 - 174.
Yao S, Chen Y, Zhuang Q , Zhang Y, Lan C, Zhu S, et al. Sniffing oxytocin: Nose to brain or nose to blood? Molecular Psychiatry. 2023:1-9. DOI: 10.1038/s41380-023-02075-2